Resource Logo

Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome.


Pediatr Nephrol. 1999 Sep;13(7):586-93. Unique Identifier : AIDSLINE

Endothelial injury is the primary pathogenic event leading to the renal thrombotic microangiopathic lesions typical of the hemolytic uremic syndrome (HUS). Basic fibroblast growth factor (bFGF) is an angiogenic growth factor released by injured endothelial cells. In a previous study we have found a significant accumulation of bFGF in human immunodeficiency virus (HIV)-transgenic mice with renal disease. Here we investigated whether bFGF was accumulated in the circulation and kidneys of two children with HIV-associated HUS (HIV-HUS), and studied the mechanisms involved in this process. The plasma levels of bFGF in children with HIV-HUS (124+/-20 pg/ml) were increased compared with five children with HIV nephropathy (49+/-6 pg/ml) and twenty HIV-infected children without renal disease (26+/-4 pg/ml, P<0.001). Immunohistochemistry and receptor binding studies showed that bFGF was accumulated bound to heparan sulfate proteoglycans in renal glomeruli and interstitium surrounding renal tubules in HIV-HUS kidneys. Basic FGF stimulated the proliferation of mesangial and urinary renal tubular epithelial cells isolated from both patients. These findings support the hypothesis that bFGF and its low-affinity binding sites may play a relevant role in modulating the process of glomerular and renal tubular regeneration during the acute stages of HIV-HUS. A follow-up study in a larger sample population is required to confirm these results.

JOURNAL ARTICLE AIDS-Associated Nephropathy/*BLOOD/METABOLISM Binding, Competitive Case Report Cell Division Child Female Fibroblast Growth Factor, Basic/*BLOOD/METABOLISM Hemolytic-Uremic Syndrome/*BLOOD/METABOLISM Human Immunoassay Immunohistochemistry Infant Kidney Tubules/PATHOLOGY Male Receptors, Fibroblast Growth Factor/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.


Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.